Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00616148 · ClinicalTrials.gov registry record · Phase 2
Efficacy of YKP3089 in Patients With Photosensitive Epilepsy
A Phase 2 study of Epilepsy, sponsored by SK Life Science.
- Completed
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
- 4
- Study locations
NCT00616148 is a Phase 2 study of Epilepsy that has completed, run by SK Life Science. The registered enrollment target is 11 participants, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (99% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT00616148, a Phase 2 study of Epilepsy, has completed, sponsored by SK Life Science.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
- 4
- Study locations
Study Summary
The aim of this study is to evaluate the ability of a single oral dose of YKP3089 to abolish or clearly reduce the IPS-induced photo-paroxysmal EEG response in photosensitive epilepsy patients, and to measure the onset and duration of the effect. Several cohorts will be used, to sequentially investigate different doses.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG YKP3089
Study Locations (4)
New York
- Cornell Medical Center - New York
- Montefiore Medical Center - The Bronx
Maryland
- Johns Hopkins Medical Center - Baltimore
Pennsylvania
- University of Pennsylvania Epilepsy Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2007-08 |
| Est. Completion | 2010-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00616148
The ClinicalTrials.gov registry entry for NCT00616148 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (99% lower). The listed sponsor is SK Life Science, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Epilepsy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00616148 reports 4 study locations spanning 3 distinct geographic areas - top geographies include New York, Maryland, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00616148 about?
NCT00616148 is a clinical study titled "Efficacy of YKP3089 in Patients With Photosensitive Epilepsy". The aim of this study is to evaluate the ability of a single oral dose of YKP3089 to abolish or clearly reduce the IPS-induced photo-paroxysmal EEG response in photosensitive epilepsy patients, and to measure the onset and duration of the effect. Several cohorts will be used, to sequentially investi...
What is the current status of trial NCT00616148?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2007-08. Estimated completion is 2010-01.
What conditions does trial NCT00616148 study?
This clinical trial studies the following conditions: Epilepsy.
What interventions are being tested in trial NCT00616148?
The interventions under investigation include: Placebo (DRUG), YKP3089 (DRUG).
Who is sponsoring clinical trial NCT00616148?
This trial is sponsored by SK Life Science, which has 25 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00616148 being conducted?
This trial has 4 study locations across Maryland, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epilepsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study
RECRUITING · Phase 2
-
A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures
RECRUITING · Phase 2
-
RNS System LGS Feasibility Study
ACTIVE NOT RECRUITING · Phase 2
-
Study of an External Responsive Neurostimulator System on Epileptiform Activity
COMPLETED · Phase 2
-
Abnormal Ventilatory Response to Carbon Dioxide: a Potential Biomarker for Seizure Induced Respiratory Depression & Modification by SSRI
COMPLETED · Phase 2
-
Hormone Replacement in Menopausal Women With Epilepsy
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.